Jagsonpal Pharmaceuticals Ltd
₹168.67
(0.01%)
Wed, 04 Mar 2026, 05:48 am
Health Technology
Pharmaceuticals: Generic
24.5KJagsonpal Pharmaceuticals Price to Sales Ratio (P/S)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 30.30 | 15.79 | 13.33 | 3.29 | 5.51 | 5.72 | 4.49 | 14.44 | 12.64 | 63.33 | 26.41 | 8.41 | 0 | 9.55 | 5.81 | 12.22 | 43.57 | 28.42 | 33.04 | 26.26 |
| Price to book ratio | 1.13 | 0.61 | 0.54 | 0.25 | 0.58 | 0.44 | 0.34 | 0.27 | 0.27 | 0.78 | 0.87 | 0.91 | 0.72 | 0.66 | 0.41 | 1.71 | 6.19 | 4.78 | 3.95 | 5.98 |
| Price to sales ratio | 0.51 | 0.34 | 0.27 | 0.15 | 0.37 | 0.25 | 0.19 | 0.16 | 0.19 | 0.54 | 0.60 | 0.69 | 0.56 | 0.41 | 0.29 | 1.11 | 3.78 | 3.21 | 3.56 | 5.41 |
| Price to cash flow ratio | 50.05 | 18.70 | 2.97 | 0.99 | 59.58 | 6.35 | 12.30 | 3.86 | 12.56 | 0 | 22.93 | 0 | 0 | 2.29 | 3.38 | 6.93 | 100.50 | 15.21 | 17.46 | 23.06 |
| Enterprise value | 1.18B | 901.15M | 749.63M | 412.21M | 655.99M | 622.94M | 585.2M | 495.5M | 501.8M | 992.49M | 1.09B | 876.83M | 642.61M | 341.52M | 123.06M | 1.53B | 7.75B | 6.51B | 6.03B | 13.35B |
| Enterprise value to EBITDA ratio | 8.70 | 8.29 | 5.95 | 2.73 | 4.17 | 4.29 | 3.52 | 4.92 | 4.70 | 11.37 | 9.21 | 14.35 | 0 | 3.66 | 1.43 | 8.01 | 29.63 | 18.40 | 25.46 | 25.82 |
| Debt to equity ratio | 0.60 | 0.68 | 0.54 | 0.35 | 0.23 | 0.31 | 0.35 | 0.34 | 0.36 | 0.41 | 0.39 | 0.07 | 0.08 | 0.04 | 0.06 | 0.06 | 0 | 0.04 | 0.05 | 0.04 |
| Return on equity % | 0 | 3.93 | 4.17 | 7.95 | 11.02 | 7.96 | 7.79 | 1.86 | 2.15 | 1.21 | 3.36 | 11.39 | -11.11 | 7.13 | 7.30 | 14.64 | 14.81 | 18.44 | 12.97 | 25.91 |
Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio
The Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Jagsonpal Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Jagsonpal Pharmaceuticals Ltd (NSE: JAGSNPHARM, BSE: 507789) is currently trading at ₹168.67, with a market capitalization of ₹11.3B. As a leading company in the Health technology sector and Pharmaceuticals: generic industry, monitoring the Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio is essential for fundamental analysis.
Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio Current Value
The current Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio stands at 5.41.
The latest Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio Historical Trend
The Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 5.41
- 2023: 3.56
- 2022: 3.21
- 2021: 3.78
- 2020: 1.11
The recent rise in Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio suggests strengthening valuation trends and improving market sentiment.
What Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio Indicates for Investors
The Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio Analysis Summary
The Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Jagsonpal Pharmaceuticals Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800